Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

Fig. 3

Prognostic capability of DTCs, CTCs, and slCTCs before and after NACT with regard to OS. Estimated survival curves adjusted for cell type status were drawn to compare OS with regard to CTCs/slCTCs in blood and DTCs in BM before and after NACT. No significant associations were found with regard to OS for every cell type tested [for DTCs, HR 1.404, 95 % CI 0.422–4.664, p = 0.5800 before therapy; HR 0.628, 95 % CI 0.142–2.786, p = 0.5406 after therapy; for CTCs, HR 1.795, 95 % CI 0.538–5.987, p = 0.3414 before NACT; HR 1.083, 95 % CI 0.137–8.550, p = 0.9400 after NACT; for slCTCs, HR 0.830, 95 % CI 0.186–3.710, p = 0.8068 before and after therapy; and not applicable (no events for slCTC-positive patients)]. BM bone marrow, CI confidence interval, CTC circulating tumor cell, DTC disseminated tumor cell, HR hazard ratio, NACT neoadjuvant chemotherapy, OS overall survival, slCTC stem cell–like circulating tumor cell

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us